{"entity":{"id":"nct07833202","kind":"trial","name":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio","aka":[],"tldr":"A phase 3 trial of IN10018, tislelizumab, carboplatin and pemetrexed in lung cancer, run by Shanghai Jeyou Pharmaceutical Co., Ltd., not yet recruiting.","summary":"A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation is a phase 3, randomised interventional study registered as NCT07833202 by Shanghai Jeyou Pharmaceutical Co., Ltd., with a registry enrolment figure of 416 participants, started 2026-10 and due to reach its primary completion in 2029-04. Interventions recorded: Sosimerasib in combination with IN10018; Tislelizumab + Carboplatin + Pemetrexed. Conditions listed: NSCLC. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: \"Histologically or cytologically documented Stage IIIB or IIIC NSCLC disease not amenable for surgical resection or definitive chemoradiation or Stage IV Non-squamous NSCLC disease\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07833202","url":"https://clinicaltrials.gov/study/NCT07833202"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["kras-g12c-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["in10018","tislelizumab","carboplatin","pemetrexed"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07833202","phase":"3","setting":"A Phase 3, Randomized, Positive Controlled, Open-Label and Multicenter Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for the Treatment of First Line Locally-advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation","sponsor":"Shanghai Jeyou Pharmaceutical Co., Ltd.","enrolled":416,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07833202/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"in10018","kind":"drug","name":"IN10018","route":"/drugs/in10018/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}